New devices aim to ease cold symptoms – but will they work?
NCT ID NCT07383493
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing four medical devices (PIR, NS, NHE, NHG) in 150 adults with acute viral rhinitis, rhinosinusitis, or rhinopharyngitis (common cold). The goal is to see if they are safe and help reduce symptoms like sneezing, runny nose, and sore throat. Participants use the device for up to 14 days and report any side effects and symptom changes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- medical devices (PIR, NS, NHE, NHG)
- What this could lead to
- If successful, this could confirm that these devices safely reduce symptoms like runny nose and congestion for people with common colds.
- What could go wrong
- This is a small, early-stage study with no placebo group, so results may not prove the devices work better than doing nothing. Side effects are possible but not well understood yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment, * Effective contraception for female patients of childbearing age. * Cooperation and sufficient understanding to comply with the requirements of the trial. * Acceptance of registration in the SI-RIPH VRB file. * Having received informed information and agreeing to give written consent. * Affiliated with the French Social Security system. Exclusion Criteria: * Hypersensitivity/history of allergy to any of the product's components, * Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated, * Chronic rhinosinusitis, * Allergic rhinosinusitis, * Other ongoing treatments for acute rhinitis (local treatment, antitussives, antibiotics, antiretrovirals, corticosteroids, etc.), * Positive antigen test for influenza A/B or COVID-19 and infection requiring etiological treatment according to the recommendations, * Bacterial rhinopharyngitis with positive TROD test * Comorbidities or health conditions deemed incompatible with the trial by the investigator, * Recent ENT surgery (\<6 months), * ENT pathology such as nasal septum deviation or other causes of nasal obstruction, * Pulmonary pathology (COPD, asthma, etc.), * Immunosuppression (as reported by the patient), * Pregnant or breastfeeding women, * Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial, * Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rhinitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Plateforme d'investigation clinique/Centre d'Investigation Clinique, Inserm CIC 1405
RECRUITINGClermont-Ferrand, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple seawater spray tame cold and sinus misery?
- AI tool aims to cut allergy misdiagnosis in primary care
- New nasal spray aims to unblock stuffy noses fast
- Which drug keeps sinus surgery cleaner? dexmedetomidine vs. nitroglycerin
- Which nasal pack is kinder to your nose after surgery?
- Sinusitis secrets: could a salt channel be the culprit?